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TO THE EDITOR
Generalized vitiligo is a disease in
which patches of depigmented skin
and overlying hair result from autoim-
mune destruction of melanocytes in
involved regions (Spritz, 2012). Clinic-
based studies cite high prevalence of
vitiligo in India, up to 8.8% (e.g., Handa
and Kaur, 1999), although population-
based surveys report much lower
prevalence, 0.46% in Calcutta (Das
et al., 1985) and 1.79% in South
Gujarat (Mehta et al., 1973).
Vitiligo is a distressing cosmetic pro-
blem in individuals of dark skin photo-
types, owing to striking contrast
between lesions and unaffected skin.
This may explain the reported high
prevalence of vitiligo in India and the
negative impact on perceived quality of
life in this population (Parsad et al.,
2003). Indeed, vitiligo has long been
recognized in India (Singh et al., 1974),
the specific use of UV light treatment
was pioneered in India (Menon, 1945),
and some of the earliest genetic studies
of vitiligo were carried out there: of
ABO blood groups, a1-antitrypsin, and
haptoglobin, and subsequent candidate
gene studies, including GCH1, ACE,
CAT, CTLA4, GPX1, IL4, MBL2, and
PTPN22, most yielding negative or
conflicting results. Recently, Singh
et al. (2012) tested the genetic asso-
ciation of vitiligo in Indian patients with
HLA-A, -B, -C in the major histocom-
patibility complex (MHC) class I region
and HLA-DRB1 in the class II region,
identifying primary genetic association
with HLA-DRB1*07:01.
Here, we describe a more compre-
hensive genetic association study of
generalized vitiligo on the Indian sub-
continent, using the Immunochip (Cortes
and Brown, 2011) to screen 196,524
single-nucleotide polymorphisms (SNPs)
in 128 loci previously implicated in
autoimmune and inflammatory diseases,
including 9,441 SNPs spanning the
extended MHC on chromosome 6p.
Our results suggest that there are at
least two independent association
signals in the MHC class II region, one
located upstream of HLA-DRA and the
other located between HLA-DRB1 and
HLA-DQA1, generally similar to what
we previously found in a genome-wide
association study of vitiligo in European-
derived whites (EUR) (Jin et al., 2010).
Our initial study group consisted of
255 patients with generalized vitiligo
and 377 unrelated non-vitiligo controls
of Indian subcontinent (Pakistan, India,
Sri Lanka, and Bangladesh) derivation.
After quality control procedures, data for
120,724 remaining SNPs from 251
remaining cases were compared with
those from 349 remaining controls. Sug-
gestive association signals were consid-
ered as clusters of nearby SNPs with
trend P-values o105. The Interna-
tional Immunochip Consortium has
agreed on a genome-wide significance
criterion of Po5 10 8 for studies
utilizing the Immunochip (Cortes and
Brown, 2011).
As shown in Figure 1a and Supple-
mentary Table S1 online, the only highly
suggestive association signals were in
the MHC class II gene region (Figure 1b),
from rs3134942 (chr6:32168770) to
rs2856674 (chr6:32659644), spanning
the upstream part of NOTCH4 through
HLA-DQB1. The principal region of
association encompassed c6orf10--
BTNL2–HLA-DRA–HLA-DRB5–HLA-
DRB1–HLA-DQA1 (Figure 1b), with
extensive linkage disequilibrium (LD)
through this region in this population
(Figure 1c). One SNP, rs482044, located
toward the centromeric end of the region,
between HLA-DRB1 and HLA-DQA1,
achieved genome-wide significance
(G allele; P¼1.94108, odds ratio
(OR)¼ 1.93; Table 1), remaining signifi-
cant (P¼4.86  108) even after
correction for the observed genomic
inflation factor l¼1.06.
To determine which SNPs in the
MHC class II region represent primary
association with vitiligo versus are sig-
nals secondary to LD, we applied a
backward regression procedure, com-
paring a model including the seven most
significant MHC class II SNPs to alter-
native models in which each SNP was
removed one by one. This analysis
suggested that this region contains two
independent associated loci, one repre-
sented by rs482044-G (located between
HLA-DRB1 and HLA-DQA1) and the
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Figure 1. Immunochip association results for generalized vitiligo. (a) The distribution of –log10(P-values) from the Cochran–Armitage trend test is shown plotted
across the chromosomes for 120,274 single-nucleotide polymorphisms that passed quality control filters in 251 cases and 349 controls. The dashed blue line
indicates the genome-wide significance criterion (Po5108) that has been agreed for studies utilizing the Immunochip (Cortes and Brown, 2011). (b) A
genomic map of the extended major histocompatibility complex (MHC), including class I and class II region of association, with the positions of rs3096691,
rs3129859, and rs482044 indicated. (c) Pattern of linkage disequilibrium (D0) observed across the MHC class II region of association.
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other represented by rs3129859-C
(located 6680 nt upstream of HLA-
DRA). Forward regression analysis of
these two SNPs showed that the model
composed of rs3129859 was signifi-
cantly (P¼ 4.4105) improved by
adding rs482044, and that the model
composed of rs482044 was significantly
improved (P¼6.0 10 4) by adding
rs3129859.
In contrast to our previous findings in
EUR (Jin et al., 2010), we observed no
apparent association of vitiligo with
SNPs in the MHC class I region in this
Indian–Pakistani population (Figure 1a
and b). Furthermore, considering loci
represented on the Immunochip that
have been reported to be associated
with vitiligo in previous candidate gene
studies from India, no SNPs in the ACE
(3 SNPs), CTLA4 (505 SNPs), or IL4 (103
SNPs) gene regions showed even nom-
inal association in the present study.
To confirm the association of general-
ized vitiligo with MHC class II region
SNPs in the Indian subcontinent, we
carried out a replication study of
rs3129859 and rs482044, as well as
the third most significant Immunochip
SNP, rs3096691 (located just upstream
of NOTCH4) (Figure 1b). These
three SNPs were genotyped in 685
unrelated generalized vitiligo cases and
774 unrelated controls from Gujarat
state, India. All three were in Hardy–
Weinberg equilibrium in the controls,
and all three achieved at least nominal
significance in the replication study
(Table 1). The most significant associa-
tion in the replication study was
observed for rs3129859-C (P¼9.48
 109), with no significant heteroge-
neity of OR between the two studies
(PBreslow–Day¼ 1.15 10 1). Cochran–
Mantel–Haenszel meta-analysis of the
rs3129859 data from the Immunochip
screen and replication study similarly
yielded the strongest overall association
(P¼ 4.3010 14, OR¼ 1.67; 95%
confidence interval 1.46–1.91). Asso-
ciation was also confirmed in the
replication study for rs482044 (P¼1.11
 104), with only nominal associa-
tion for rs3096691 (P¼ 2.32 102),
although both of these SNPs exhibited
heterogeneity of OR. Both rs482044
(P¼ 1.5810 2) and rs3129859
(P¼ 1.2010 6) remained significant
when each was conditioned on the
other. Overall, our findings thus gener-
ally confirm the association of vitiligo
with at least two independent loci in the
MHC class II region.
In a previous genome-wide associa-
tion study of generalized vitiligo in EUR
subjects, we found that both vitiligo
susceptibility (Jin et al., 2010) and age
of onset (Jin et al., 2011) are similarly
associated with at least two independent
loci in the MHC class II region. To
assess whether the MHC class II loci
observed in the Indian subcontinent and
EUR populations might correspond
ancestrally, we carried out trans-ethnic
meta-analysis using MANTRA (Morris,
2011), which indicated that the MHC
association signal represented by
rs482044 in the Indian subcontinent
population apparently corresponds to
the MHC signal represented by
rs532098 in EUR (Jin et al., 2010)
(Supplementary Table S2 online). In
contrast, rs3129859 is not significantly
associated with vitiligo in EUR (Jin et al.,
2010), and the correspondence between
the association signals upstream of HLA-
DRA observed in both populations
remains uncertain.
Our findings thus highlight both simi-
larity and differences of vitiligo MHC
genetic associations in subjects from
different major world populations. In
the Indian subcontinent, this study and
that of Singh et al. (2012) support the
association of vitiligo with loci in the
MHC class II region, but show no
primary association in the MHC class I
region. Similarly, in the EUR population,
vitiligo is also associated with multiple
signals in the MHC class II region, at
least one of which, between HLA-DRB1
and HLA-DQA1, appears to correspond
to one in the Indian subcontinent
population. However, in the EUR
population vitiligo shows primary
association with HLA-A in the distal
class I region (Jin et al., 2010),
specifically HLA-A*02:01 (Jin et al.,
2012). In addition, studies in the
Chinese population show principal
MHC association in the class III region
(Quan et al., 2010) and in the proximal
class I region, between HLA-B and
HLA-C (Liu et al., 2012). Together,
these similarities and differences of
principal MHC genetic associations
with generalized vitiligo among
different populations may partly
underlie differing prevalence of this
autoimmune disease in different groups
around the world.
This study was approved by the
Combined Institutional Review Board
(COMIRB) of the University of Color-
ado–Denver, Aurora, CO, USA; by the
Ethics Committee of King Edward Med-
ical University, Lahore, Pakistan; and by
the Institutional Ethical Committee for
Human Research (IECHR) of The
Maharaja Sayajirao University of Bar-
oda, Gujarat, India, and was conducted
in accord with the Declaration of
Table 1. MHC class II region SNPs genotyped in Immunochip screening and in replication studies
Immunochip study Replication study Meta-analysis
SNP Nt A1 A2 Trend P OR Trend P OR Meta-P1 OR PBreslow–Day
rs3096691 32194853 G A 3.99 107 1.81 2.32 10 2 1.18 8.04 102 1.45 1.35 10 3
rs3129859 32400938 C G 1.91 107 2.00 9.48 10 9 1.60 4.30 1014 1.67 1.15 10 1
rs482044 32576063 G C 1.94 108 1.93 1.11 10 4 1.33 1.32 102 1.58 5.34 10 3
Abbreviations: A1, effect allele; A2, reference allele; MHC, major histocompatibility complex; nt, nucleotide (chromosome 6, GRCh37/hg19); OR, odds ratio;
SNP, single-nucleotide polymorphism.
1Meta-analysis P-value and OR for rs3129859 was calculated by the Cochran–Mantel–Haenszel method; meta-analysis P-values and ORs for rs3096691 and
rs482044 were calculated under a random-effects model using results from logistic regression analysis because of significant PBreslow–Day heterogeneity.
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Helsinki Principles. Written informed
consent was obtained from all study
subjects.
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TO THE EDITOR
Neurofibromatosis type I (NF1) is one of
the most common autosomal dominant
inherited diseases affecting 1 in 3,500
individuals. It is caused by a germline
mutation in the tumor suppressor gene
NF1 (Viskochil et al., 1990; Wallace
et al., 1990). Hallmarks are the develo-
pment of cafe´ au lait spots and dermal
as well as plexiform neurofibromas
(Riccardi, 1999). Neurofibromas are
heterogeneous tumors composed of
Schwann cells (SCs) in addition to fibro-
blasts, perineurial cells, mast cells, and
lymphocytes (Serra and Rosenbaum,
2000). An additional somatic mutation
in the second copy of the NF1 gene in a
SC population is an essential early step
for neurofibroma formation (Zhu et al.,
2002). In neurofibroma tissues both cells
with biallelic NF1 inactivation ( / )
and those still bearing an intact copy of
the NF1 gene (þ / ) are present (Serra
and Rosenbaum, 2000).
In a suppressive subtractive hybridi-
zation screen comparing mRNA pools
of human neurofibroma derived þ /
and  / SCs, we identified the major
histocompatibility complex (MHC) class
II family to be differentially expressed.
MHCII genes are normally highly
expressed selectively on professional
antigen presenting immune cells
(Krawczyk and Reith, 2006). However,
expression has also been detected in
several solid tumors such as malignant
melanoma and glioma (Tran et al.,
1998; Campoli and Ferrone, 2008).
We generated highly enriched cul-
tures of NF1þ / and NF1 / SCs
from neurofibromas, as well as
NF1þ /þ normal human SCs from per-
ipheral nerves. NF1þ / and NF1 /
SCs were enriched from the same neu-
rofibroma tissue derived from patients
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